What’s the Buzz? Cannabis-derived products are at a dynamic legal and regulatory crossroads at both the state and federal level. While cannabis-derived substances above 0.3% THC are still illegal at the federal level, states are continuing to legalize cannabis for medical and/or recreational use; many states even designated cannabis businesses as “essential” during the initial phases of the COVID-19 pandemic. Simultaneously, CBD products, many with unsubstantiated drug claims or containing toxic substances, continue to proliferate despite scant FDA oversight. This conference will examine the present reality of this unique industry from both a legal and practical perspective and guide attendees on how to navigate this constantly changing legal environment. Industry experts will untangle the issues related to CBD, cannabis, and other cannabinoids, various regulated product areas (e.g., topicals, supplements, edibles, vapes), and state vs. federal regulation.
- The current federal regulatory landscape for CBD-derived products
- CBD safety, product quality, labeling, and marketing considerations
- CBD litigation and enforcement trends
- Updates on the Agriculture Improvement Act of 2018 implementation
- Cannabis state legalization developments
- Cannabis research initiatives and regulatory updates
- Impacts of COVID-19 and the Black Lives Matter movement on the cannabis industry
Call For Proposals
FDLI and the Conference Planning Committee thanks those who participated in the Call for Proposals this summer. The input received from industry stakeholders helps us plan a timely program. If you submitted a proposal, you will be notified of the status of your proposal in September.
Libby Baney, Faegre Drinker
Linda D. Bentley, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Kelly Fair, Canopy Growth Corporation
William A. Garvin, Buchanan Ingersoll & Rooney PC
Steven N. Levine, Husch Blackwell LLP
Brian J. Malkin, McDermott Will & Emery
Keith Matthews, Wiley LLP
Daniel McGee, Solari Hemp
Douglas MacKay, CV Sciences
Debby Miran, Entourage Therapeutics, LLC
Heike Newman, Senior Regulatory Manager, University of Colorado
Megan L. Olsen, Council for Responsible Nutrition
Christopher Van Gundy, Sheppard Mullin Richter & Hampton LLP
Deborah Walter, Greenwich Biosciences
Daniel Wang, Pinney Associates, Inc.
Jessica Anne Wasserman, Greenspoon Marder LLP